deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02224729

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase II Study of Bendamustine, Bortezomib, and Dexamethasone (BBD) for Newly Diagnosed Patients With Multiple Myeloma

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Conditions Stage I Multiple Myeloma Stage II Multiple Myeloma Stage III Multiple Myeloma
Interventions Bendamustine hydrochloride Bortezomib Dexamethasone
Updated 15 times since 2017 Last updated: Apr 28, 2025 Started: Aug 25, 2014 Primary completion: Apr 21, 2016 Completion: Nov 17, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Stage I Multiple Myeloma and Stage II Multiple Myeloma, this trial is completed. The trial is conducted by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University and has accumulated 15 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Nov 2017 · 9 months · monthly snapshot~Nov 2017 – ~Feb 2018 · 3 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Oct 2019 · 14 months · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Feb 2026 · 9 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

  2. May 2025 — Feb 2026 [monthly]

    Completed PHASE2

  3. Sep 2024 — May 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 10 earlier versions

  1. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  2. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

  3. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Aug 2018 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  7. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Nov 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Feb 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations